MediciNova's Ibudilast Wins FDA Fast Track for ALS

The FDA has granted fast track designation to MediciNova’s ibudilast for patients with amyotrophic lateral sclerosis.

Marketed in Japan and Korea since 1989 for post-stroke complications and bronchial asthma, the candidate suppresses pro-inflammatory cytokines and promotes neurotrophic factors. MediciNova licensed the product from Kyorin Pharmaceutical for its potential in relapse-remitting multiple sclerosis.